Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Updated on: January 04,2024 9

Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Updated on:January 04,2024 9

Double testing better at identifying bowel cancer

byUniversity of EdinburghReceiver operating characteristic (ROC) curve analysis for the detection of colorectal cancer between cohorts. Area under the curve 0.85 (95% c.i. 0.80 to 0.90) for the

Updated on: January 04,2024 8

Double testing better at identifying bowel cancer

byUniversity of EdinburghReceiver operating characteristic (ROC) curve analysis for the detection of colorectal cancer between cohorts. Area under the curve 0.85 (95% c.i. 0.80 to 0.90) for the

Updated on:January 04,2024 8

Small risks may have big impact on breast cancer odds of childhood cancer survivors

bySt. Jude Children's Research HospitalZhaoming Wang, Ph.D., used data from the St. Jude Lifetime Cohort study to find evidence that common genetic variations can help to identify pediatric

Updated on: December 18,2023 23

Small risks may have big impact on breast cancer odds of childhood cancer survivors

bySt. Jude Children's Research HospitalZhaoming Wang, Ph.D., used data from the St. Jude Lifetime Cohort study to find evidence that common genetic variations can help to identify pediatric

Updated on:December 18,2023 23

Predicting prostate cancer recurrence 15 months sooner

by Steve Martin,Purdue UniversityGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.105430A Purdue University mechanical engineer and his international collaborators

Updated on: January 06,2024 17

Predicting prostate cancer recurrence 15 months sooner

by Steve Martin,Purdue UniversityGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.105430A Purdue University mechanical engineer and his international collaborators

Updated on:January 06,2024 17

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

by Kyoto UniversityDYRK1A bound to FAM53C in the cytoplasm is less active. DYRK1A not bound to FAM53C in the nucleus is highly active. Functional abnormalities cause various neuropsychiatric deve

Updated on: February 20,2024 13

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

by Kyoto UniversityDYRK1A bound to FAM53C in the cytoplasm is less active. DYRK1A not bound to FAM53C in the nucleus is highly active. Functional abnormalities cause various neuropsychiatric deve

Updated on:February 20,2024 13

Perspective on management of LDCT findings on low-dose computed tomography examinations for lung cancer screening

by International Association for the Study of Lung CancerTop 10 global causes of deaths,2016. Credit:Journal of Thoracic Oncology(2023). DOI: 10.1016/j.jtho.2023.11.013Annual low-dos

Updated on: December 28,2023 15

Perspective on management of LDCT findings on low-dose computed tomography examinations for lung cancer screening

by International Association for the Study of Lung CancerTop 10 global causes of deaths,2016. Credit:Journal of Thoracic Oncology(2023). DOI: 10.1016/j.jtho.2023.11.013Annual low-dos

Updated on:December 28,2023 15

Cooling glioblastoma to room temperature extends survival in preclinical study

by Jenny Owen,Emory UniversityConceptual model of a translational device to deliver cytostatic hypothermia for GBM. Representative diagram of a patient with GBM implanted with an envisioned cyto

Updated on: January 30,2024 10

Cooling glioblastoma to room temperature extends survival in preclinical study

by Jenny Owen,Emory UniversityConceptual model of a translational device to deliver cytostatic hypothermia for GBM. Representative diagram of a patient with GBM implanted with an envisioned cyto

Updated on:January 30,2024 10

Trial demonstrates acute lymphoblastic leukemia treatment advance

by Diane Dragaud, ECOG-ACRIN Cancer Research GroupCredit:LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblas

Updated on: January 04,2024 9

Trial demonstrates acute lymphoblastic leukemia treatment advance

by Diane Dragaud, ECOG-ACRIN Cancer Research GroupCredit:LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblas

Updated on:January 04,2024 9

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030

Updated on: January 26,2024 10

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030

Updated on:January 26,2024 10

Development and application of competing risks and multi-state models in cancer epidemiology

byKarolinska InstitutetCredit: Unsplash/CC0 Public DomainCompeting risks and multi-state models allow us to study complex disease settings and answer composite research questions and should be u

Updated on: December 18,2023 10

Development and application of competing risks and multi-state models in cancer epidemiology

byKarolinska InstitutetCredit: Unsplash/CC0 Public DomainCompeting risks and multi-state models allow us to study complex disease settings and answer composite research questions and should be u

Updated on:December 18,2023 10

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

by Perelman School of Medicine at the University of PennsylvaniaSafety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with

Updated on: January 26,2024 20

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

by Perelman School of Medicine at the University of PennsylvaniaSafety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with

Updated on:January 26,2024 20

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

Updated on: March 22,2024 17

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

Updated on:March 22,2024 17